{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T09:03:27Z","timestamp":1772355807955,"version":"3.50.1"},"reference-count":31,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2021,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Immune checkpoint inhibitor (ICI) use in advanced hepatocellular carcinoma (HCC) is increasing. Real\u2010world data on efficacy and safety, however, are lacking.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective review of all patients with advanced HCC seen at our center who received at least one dose of an ICI between May 2015 and June 2018. Data cutoff was December 31, 2018. Responses were evaluated using Response Evaluation Criteria in Solid Tumors version 1.1 criteria.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 114 patients, 88.6% were male. Median age was 66 years, 96.5% had an Eastern Cooperative Oncology Group of 0\u20131. 62.3% received monotherapy ICI. 18.4% of patients had Child\u2010Pugh (CP) B disease on initiation of ICI, and 69.3% had an ALBI grade of 2. 54.4% were known to have chronic hepatitis B (HBV) or were previously infected, and 11.4% had hepatitis C. Baseline HBV viral load (VL) ranged from undetectable to 8\u00a0210\u00a0000 IU\/mL. 35.1% received prior systemic treatment. 28.9% received prior sorafenib. Over a median follow\u2010up duration of 13.8 months (10.4\u201315.8), ORR was 18.4%, and DCR was 50.9%. Median progression\u2010free survival was 2.7 months (1.3\u20134.0), and median overall survival (OS) was 13.9 months (6.9\u201316.2). Thirty\u2010one patients (27.2%) received further systemic therapy after ICI discontinuation. On multivariable analyses, lower albumin level, higher bilirubin level, diuretic\u2010refractory ascites, and HBV\u2010associated HCC were associated with poorer OS. 69.3% of patients experienced adverse events (AE) of any grade, 14.9% of these being grade 3\u20134. No grade 5 AE were observed. Use of antiviral therapy was associated with a lower risk of grade 3 or above hepatic AEs (<jats:italic>P<\/jats:italic>\u00a0=\u00a00.048), whereas high baseline HBV VL was not associated with an increased risk of reactivation or hepatic AE.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>We have demonstrated that the real\u2010world performance of ICIs in advanced HCC appears comparable to that observed in clinical trials for HCC patients with CP A cirrhosis. While prognosis of patients with advanced HCC and CP B cirrhosis remains poor even with ICI, usage of ICI is likely to be safe. Patients with HBV with a baseline HBV VL \u2265100 IU\/mL may receive ICI safely, especially if they are on antiviral treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.13454","type":"journal-article","created":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T06:54:06Z","timestamp":1599029646000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Real\u2010world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center"],"prefix":"10.1111","volume":"17","author":[{"given":"Kennedy Yao Yi","family":"Ng","sequence":"first","affiliation":[{"name":"Division of Medical Oncology National Cancer Centre Singapore  Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence Wen Jun","family":"Wong","sequence":"additional","affiliation":[{"name":"Yong Loo Lin School of Medicine National University of Singapore  Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Jing Shi","family":"Ang","sequence":"additional","affiliation":[{"name":"Yong Loo Lin School of Medicine National University of Singapore  Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sze Huey","family":"Tan","sequence":"additional","affiliation":[{"name":"Division of Clinical Trials and Epidemiological Sciences National Cancer Centre Singapore  Singapore"},{"name":"Oncology Academic Programme Duke\u2010NUS Medical School  Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su Pin","family":"Choo","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology National Cancer Centre Singapore  Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2612-0065","authenticated-orcid":false,"given":"David Wai\u2010Meng","family":"Tai","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology National Cancer Centre Singapore  Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1070-6125","authenticated-orcid":false,"given":"Joycelyn Jie Xin","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology National Cancer Centre Singapore  Singapore"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,9]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21492"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.4004"},{"issue":"5","key":"e_1_2_14_6_1","article-title":"LBA38_PRCheckMate 459: A randomized, multi\u2010center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first\u2010line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)","volume":"30","author":"Yau T","year":"2019","journal-title":"Ann Oncol"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900080504"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.e15675"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2780-8"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15245"},{"key":"e_1_2_14_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.e16149"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32206"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30237"},{"issue":"8","key":"e_1_2_14_14_1","article-title":"699PReal\u2010world data on nivolumab treatment in Asian patients with advanced hepatocellular carcinoma","volume":"29","author":"Yoon SE","year":"2018","journal-title":"Ann Oncol"},{"key":"e_1_2_14_15_1","unstructured":"Common Terminology Criteria for Adverse Events Version 4.03. In: National Institutes of Health NCI editor;2010."},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.161"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.7.2324"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2008.01957.x"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.4_suppl.475"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz446.002"},{"key":"e_1_2_14_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS4144"},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4152"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000042"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30569-1"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.4_suppl.327"},{"issue":"2","key":"e_1_2_14_27_1","first-page":"40","article-title":"Safety and efficacy of sorafenib in patients with hepatocellular carcinoma (HCC) and Child\u2010Pugh A versus B Cirrhosis","volume":"4","author":"Abou\u2010Alfa GK","year":"2011","journal-title":"Gastrointest Cancer Res"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.020"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.3892\/mco.2015.536"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)30249-6"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh430"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1743-7563.2012.01534.x"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13454","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.13454","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13454","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T21:56:32Z","timestamp":1693346192000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.13454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["10.1111\/ajco.13454"],"URL":"https:\/\/doi.org\/10.1111\/ajco.13454","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"2020-07-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-10","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}